ClinicalTrials.gg
CompletedNCT03841396Updated Feb 15, 2019

A Study Comparing the Local Tolerability of Two Subcutaneous Heparins in Healthy Volunteers.

A Phase 4 interventional study of Sodium chloride in Injection Site Reaction, sponsored by Aspen Global Incorporated. Completed. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2019-02-15.

Sponsored by Aspen Global Incorporated · Phase 4, Interventional, and Other

From the registry’s dates

  • Registered 2 years 7 months after the study started (first participant enrolled Jun 2016, registered Jan 2019).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
15
Allocation
Randomized
Ages
18 Years to 55 Years
Sex
All
01

Study summary

A Phase IV, Randomised, Double-blind, Single-centre clinical trial in healthy male and female participants aged 18 to 55, that was designed to assess and compare the pain intensity at an injection site as well as the duration of pain following a single dose subcutaneous administration of two low molecular weight heparins (LMWH) respectively.

Read the detailed description

This was a Phase IV, Randomised, Double-blind, Single-centre clinical trial in healthy male and female participants aged 18 to 55, that was designed to assess and compare the pain intensity at an injection site as well as the duration of pain following a single dose subcutaneous administration of two LMWHs respectively. This study included an approximate seven-day screening period (screening visit to day 0), followed by three visits (Visit 2, 3 and 4) in one-week intervals, in which each participant should have received a single sequence of subcutaneous injections of Placebo, Fraxiparine and Clexane, in a randomised order, on the three separate occasions. This was then followed by a safety follow-up visit, one week after the administration of the last dose of the study product.

Fifteen (N = 15) healthy, consenting participants, fulfilling the inclusion criteria, were randomised to take part in this study. All participants received a single sequence of subcutaneous injections, on separate occasions at one week intervals, over the duration of the treatment phase of the study. Fifteen (N=15) participants received Fraxiparine, fifteen (N=15) participants received Clexane and fifteen (N=15) participants received Placebo. Two participants were screened however did not meet the eligibility criteria and therefore were not included into the study. Informed consent was obtained at Screening Visit 1 (day -7 to 0) before any trial-related procedures were be performed. Visual analogue and 11-point numeric rating scales were utilised to measure pain intensity after a single injection of investigational product. These scales were also used to assess burning and pruritus. All scales were be completed at set time intervals over a 30 minute period, i.e. 1, 3, 5, 10, 15 and 30 minutes after the injections were completed. Hematoma, erythema and oedema were measured minutes and 1, 2 and 3 days after the injection, using transparent millimetric measuring paper. Safety bloods were drawn at each visit.

02

Conditions studied

  • Injection Site Reaction
03

In context

Injection Site Reaction

22 studies on the registry are indexed under Injection Site Reaction; 3 are open to participants now.

This study's enrollment of 15 is below the median of 60 across 17 interventional studies indexed under Injection Site Reaction.

Browse Injection Site Reaction studies →

Lead sponsor

Aspen Global Incorporated is the lead sponsor of 2 studies on the registry; none are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Male or Female participant.
  2. Aged 18 years to 55 years.
  3. Medically healthy participants.
  4. Weight Females: ≥ 45 kg; Males ≥ 57 kg.
  5. (BMI) of 18,5 to 29,9 kg/m2.
  6. Female participants of must have a negative urine pregnancy test at screening and be willing to use effective throughout the trial duration.
  7. Participants must be able to understand and follow the instructions of the Investigator, understand and give , and be willing, committed, and able to return for all site visits and complete all study-related procedures.

Exclusion criteria

Exclusion Criteria:

  1. A known to Clexane or Fraxiparine or any components thereof - especially allergies to latex, pork products, sulfites and benzyl alcohols.
  2. Female participants who are pregnant or lactating.
  3. Any coagulopathy - Anaemia, thrombocytopenia, hemophilia, haemorrhagic diathesis (Bleeding, Bruising, Clotting disorders).
  4. Active gastric or duodenal ulcer or history of previous gastric duodenal bleeding or gastrointestinal bleeding.
  5. Participants on the following medications: Anti-coagulants, Non-Steroidal Anti-inflammatory Drugs (NSAID)s, glycoprotein IIb/IIIa anticoagulants, thrombolytic agents, -inhibitors, acetylsalicylic acid, sulfinpyrazone, quinine - containing remedies and/drinks, treprostinil, apixaban, drotecogin alfa, danshen, dong quai, evening primrose oil, gingko, policosanol and willow bark as well as hyperkalemia aggravators in the last 7 days.
  6. A Cerebrovascular incident (hemorrhagic or ischemic).
  7. Deep Vein Thrombosis and/ Pulmonary embolism.
  8. Acute infective endocarditis or history of acute endocarditis.
  9. Participants with Hypertension.
  10. Diabetics.
  11. Any injuries or surgery of the ears, eyes, brain or spinal cord within the last 18 months.
  12. Renal insufficiency (Creatinine and Urea not within normal ranges).
  13. Hepatic Insufficiency ( (AST) and alanine transaminase (ALT) within normal ranges).
  14. Participants with Heamorrhagic Retinopathy.
  15. Participants with prosthetic heart valve/s.
  16. Participants currently receiving any other treatments administered via subcutaneous or intramuscular routes.
  17. Participants with a history or current endocrine, pulmonary, cardiovascular, gastrointestinal, neurological, immunological, renal, hepatic, dermatologic, haematologic, psychiatric disease other than specified that might have/cause unwanted effects/outcomes in this clinical trial.
  18. Alcohol and/ or drug abuse in the past year.
  19. In the opinion of the investigator, the participant is not reliable to participate in the trial.
  20. Participants that have taken part in a clinical trial involving Clexane and/ Fraxiparine.

    -

Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

05

Study design

Phase
Phase 4
Primary purpose
Other
Allocation
Randomized
Intervention model
Single group
Masking
Double (Participant, Investigator)
Enrollment
15 participants (actual)

Study arms

  • Active comparator
    Fraxiparine

    Nadroparine, Pre-filled syringe, 3800IU, single dose

    Drug: Sodium chloride

  • Active comparator
    Clexane

    Enoxaparin, Pre-filled syringe, 40 mg, single dose

    Drug: Sodium chloride

Interventions

  • All participants received a single dose of sodium chloride as placebo

    Also known as: Saline 0.4mL saline

06

What researchers measure

Primary outcomes

  1. Comparison of Visual Analog Scale (VAS) scores of pain intensity at injection site following a single subcutaneous injection of placebo, Fraxiparine or Clexane

    Visual Analogue Scales for pain intensity was performed at different time points namely 1, 3, 5, 10, 15 and 30 minutes after administration of the investigational product (IP) at Visit 2, 3 and 4. Pain intensity: 0 mm - No pain; 100 mm - Worst pain

    Time frame: Over a period of 30 minutes

  2. Comparison of Numeric Rating Scale (NRS) scores of pain intensity at injection site following a single subcutaneous injection of placebo, Fraxiparine or Clexane.

    11-point NRS for pain intensity was performed at different time points namely 1, 3, 5, 10, 15 and 30 minutes after administration of the investigational product (IP) at Visit 2, 3 and 4. Pain intensity: 0 - No pain; 10 - Worst pain

    Time frame: Over a period of 30 minutes

Secondary outcomes

  1. Quantification of local injection site reaction

    Hematoma, erythema and oedema were measured 10 and 30 minutes and 1, 2 and 3 days after the injection, using transparent millimetric measuring paper.

    Time frame: 10 and 30 minutes and 1, 2 and 3 days after the injection.

  2. Pain duration

    Duration of pain at injection site.

    Time frame: 1, 3, 5, 10, 15 and 30 minutes after administration of IP.

07

Study locations

No study locations are listed for this record.

08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jun 2016 to primary completion in Jul 2016, 1 month.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 29, 2019
First posted
Feb 15, 2019
StartActual
Jun 2, 2016
Primary completionActual
Jul 15, 2016
CompletionActual
Jul 15, 2016
Last update
Feb 15, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 15, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03841396
Lead sponsor
Aspen Global Incorporated
Responsible party
Sponsor
First posted
Feb 15, 2019
Start date
Jun 2, 2016
Primary completion
Jul 15, 2016
Completion
Jul 15, 2016
Last update
Feb 15, 2019

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Sodium Chloride

Start the discussion